-
Before giving a stroke patient tissue plasminogen activator (tPA), you must consider not only whether the patent is a candidate, but also whether the setting is appropriate, says Edward Jauch, MD, MS, assistant professor in the department of emergency medicine at University of Cincinnati and a member of the Greater Cincinnati/Northern Kentucky Stroke Team.
-
-
Emergency physicians are much more likely to be sued for not administering tissue plasminogen activator (tPA) to stroke patients, than for giving the drug, says a new study.
-
You are treating a patient that you feel would be a good candidate for 'Drug X.' Unfortunately, 'Drug X' is not indicated by the FDA for the treatment of that specific condition; and, you are unable to find prescribing information regarding the optimal dose or duration of therapy with 'Drug X' for that condition. You realize that your use of 'Drug X' in this circumstance would be considered "off-label." What legal risks, if any, might you face?
-
In This Issue: FDA drug approval to change? Urinary incontinence in women; how metabolism of certain drugs can be predicted by genetic analysis; bowel preps may compromise renal function especially in the elderly according to a new study; FDA Actions.
-
A prospective, observational study was conducted in Buenos Aires, Argentina, during 2003-2004 among 216 healthy infants > 32 weeks gestation who received age-appropriate immunizations, as routinely administered in Argentina.
-
-
The Caribbean receives scant attention from HIV researchers and public health officials, and this has resulted in an epidemic that is poorly understood, an investigator says.
-
-
Once a privacy breach occurs with a patient's medical records, the risk manager must act quickly and decisively, says Layna Cook, JD, an attorney specializing in health care risk management with the law firm McGlinchey Stafford in Baton Rouge, LA. The Health Insurance Portability and Accountability Act (HIPAA) requires mitigation when a violation occurs, Cook notes.
